Entering text into the input field will update the search result below

Cellectis SA (CLLS) Q1 2023 Earnings Call Transcript

May 05, 2023 1:15 PM ETCellectis S.A. (CLLS), CMVLF1 Comment
SA Transcripts profile picture
SA Transcripts

Cellectis SA (NASDAQ:CLLS) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET

Company Participants

Arthur Stril - Chief Business Officer

Andre Choulika - Co-Founder, CEO & Director

Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer

Bing Wang - CFO

Conference Call Participants

Gena Wang - Barclays Bank

Yigal Nochomovitz - Citigroup

Anoumid Vaziri - Goldman Sachs Group

Dev Prasad - Jefferies

Hartaj Singh - Oppenheimer

Jack Allen - Robert W. Baird & Co.

Ingrid Gafanhao - Kempen

Silvan Tuerkcan - JMP Securities


Good morning, everyone, and welcome to Cellectis First quarter 2023 Earnings Call. [Operator Instructions].

Please be aware that today's conference call is being recorded. I'd now like to introduce the first speaker, Arthur Stril, Chief Business Officer. Please go ahead, sir.

Arthur Stril

Good morning, and welcome, everyone, to Cellectis' First Quarter 2023 Corporate Updates and Financial Results Conference Call.

Joining me on the call today with prepared remarks are Dr. Andre Choulika, our Chief Executive Officer; Dr. Bing Wang, our Chief Financial Officer; and Dr. Mark Frattini, our Chief Medical Officer.

Yesterday evening, Cellectis issued a press release reporting its financial results for the 3-month period ended March 31, 2023. The report and press release are available on our website at www.cellectis.com.

As a reminder, we will make statements regarding Cellectis' financial outlook in addition to its manufacturing, regulatory and product development standards and plans and product development of its license partners. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our license partners are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Securities and Exchange

Recommended For You

Comments (1)

This company has been around for over two decades, and has had very interesting technology in both the pharma and ag fields. Management in both fields has been disastrous, continuously pissing away shareholder money with nothing but early-stage hope to discuss. The only shareholder prospect would seem to be an acquisition by a bargain hunter to acquire the IP.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About CLLS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CLLS

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.